Galapagos creates new warrant plan
April 19 2018 - 04:01PM
Mechelen, Belgium; 19 April 2018, 22.01 CET;
regulated information -- Galapagos NV (Euronext & NASDAQ:
GLPG) announced today that its board of
directors created 1,585,000 warrants under new warrant plans for
the benefit of employees, future employees, directors and a
consultant of the company and its subsidiaries.
On 19 April 2018, the board of
directors of Galapagos approved the "Warrant Plan 2018", a warrant
plan intended mainly for certain (future) employees of the company
and its subsidiaries, and also for directors and an independent
consultant of the company, and the "Warrant Plan 2018 RMV," a
warrant plan intended for certain employees of its French
subsidiary, Galapagos SASU, within the framework of the authorized
capital. Under these warrant plans, 1,585,000 warrants were
created, subject to acceptances, and offered to the beneficiaries
of the plans.
The offer of warrants to directors
remains subject to approval of the annual shareholders' meeting to
be held on 24 April 2018.
The warrants have an exercise term
of eight years as of the date of the offer and have an exercise
price of €79.88 (the average closing price of the share on
Euronext Amsterdam and Brussels during the thirty days preceding
the date of the offer). The warrants are not transferable and can
in principle not be exercised prior to 1 January 2022. Each warrant
gives the right to subscribe to one new Galapagos share. Should the
warrants be exercised, Galapagos will apply for the listing of the
resulting new shares on a regulated stock market. The warrants as
such will not be listed on any stock market.
Galapagos' total share capital
currently amounts to €277,122,928.92; the total number of
securities conferring voting rights is 51,234,962, which is also
the total number of voting rights (the "denominator"), and all
securities conferring voting rights and all voting rights are of
the same category. The total number of rights (warrants) to
subscribe to not yet issued securities conferring voting rights is
3,660,623, which equals the total number of voting rights that may
result from the exercise of these warrants, and excludes the
1,585,000 warrants of Warrant Plan 2018 and Warrant Plan 2018
RMV, which were created subject to acceptance. Galapagos does not
have any convertible bonds or shares without voting rights
outstanding.
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage
biotechnology company specialized in the discovery and development
of small molecule medicines with novel modes of action. Galapagos'
pipeline comprises Phase 3 through to discovery programs in cystic
fibrosis, inflammation, fibrosis, osteoarthritis and other
indications. Our target discovery platform has delivered three
novel mechanisms showing promising patient results in,
respectively, inflammatory diseases, idiopathic pulmonary fibrosis
and atopic dermatitis. Galapagos is focused on the development and
commercialization of novel medicines that will improve people's
lives. The Galapagos group, including fee-for-service subsidiary
Fidelta, has approximately 600 employees, operating from its
Mechelen, Belgium headquarters and facilities in the Netherlands,
France, Switzerland, the United States and Croatia. More
information at www.glpg.com.
Investors:
Elizabeth Goodwin
VP IR & Corporate Communications
+1 781 460 1784
Paul van der Horst
Director IR & Business Development
+31 71 750 6707
ir@glpg.com
Media:
Evelyn Fox
Director Communications
+31 6 53 591 999
communications@glpg.com
Forward-looking statements
This release may contain forward-looking
statements. Such forward-looking statements are not guarantees of
future results. These forward-looking statements speak only as of
the date of publication of this document. Galapagos expressly
disclaims any obligation to update any forward-looking statements
in this document, unless specifically required by law or
regulation.
Warrant plan
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Galapagos NV via Globenewswire
Galapagos NV (NASDAQ:GLPG)
Historical Stock Chart
From Feb 2024 to Mar 2024
Galapagos NV (NASDAQ:GLPG)
Historical Stock Chart
From Mar 2023 to Mar 2024